1016 related articles for article (PubMed ID: 32738193)
1. A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition.
Dieterle ME; Haslwanter D; Bortz RH; Wirchnianski AS; Lasso G; Vergnolle O; Abbasi SA; Fels JM; Laudermilch E; Florez C; Mengotto A; Kimmel D; Malonis RJ; Georgiev G; Quiroz J; Barnhill J; Pirofski LA; Daily JP; Dye JM; Lai JR; Herbert AS; Chandran K; Jangra RK
Cell Host Microbe; 2020 Sep; 28(3):486-496.e6. PubMed ID: 32738193
[TBL] [Abstract][Full Text] [Related]
2. Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2.
Case JB; Rothlauf PW; Chen RE; Liu Z; Zhao H; Kim AS; Bloyet LM; Zeng Q; Tahan S; Droit L; Ilagan MXG; Tartell MA; Amarasinghe G; Henderson JP; Miersch S; Ustav M; Sidhu S; Virgin HW; Wang D; Ding S; Corti D; Theel ES; Fremont DH; Diamond MS; Whelan SPJ
Cell Host Microbe; 2020 Sep; 28(3):475-485.e5. PubMed ID: 32735849
[TBL] [Abstract][Full Text] [Related]
3. Replication-Competent Vesicular Stomatitis Virus Vaccine Vector Protects against SARS-CoV-2-Mediated Pathogenesis in Mice.
Case JB; Rothlauf PW; Chen RE; Kafai NM; Fox JM; Smith BK; Shrihari S; McCune BT; Harvey IB; Keeler SP; Bloyet LM; Zhao H; Ma M; Adams LJ; Winkler ES; Holtzman MJ; Fremont DH; Whelan SPJ; Diamond MS
Cell Host Microbe; 2020 Sep; 28(3):465-474.e4. PubMed ID: 32798445
[TBL] [Abstract][Full Text] [Related]
4. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
[TBL] [Abstract][Full Text] [Related]
5. A replication-competent vesicular stomatitis virus for studies of SARS-CoV-2 spike-mediated cell entry and its inhibition.
Dieterle ME; Haslwanter D; Bortz RH; Wirchnianski AS; Lasso G; Vergnolle O; Abbasi SA; Fels JM; Laudermilch E; Florez C; Mengotto A; Kimmel D; Malonis RJ; Georgiev G; Quiroz J; Barnhill J; Pirofski LA; Daily JP; Dye JM; Lai JR; Herbert AS; Chandran K; Jangra RK
bioRxiv; 2020 May; ():. PubMed ID: 32511365
[TBL] [Abstract][Full Text] [Related]
6. Establishment of replication-competent vesicular stomatitis virus recapitulating SADS-CoV entry.
Zhu Z; Han Y; Gong M; Sun B; Zhang R; Ding Q
J Virol; 2024 May; 98(5):e0195723. PubMed ID: 38557247
[TBL] [Abstract][Full Text] [Related]
7. Establishment of replication-competent vesicular stomatitis virus-based recombinant viruses suitable for SARS-CoV-2 entry and neutralization assays.
Li H; Zhao C; Zhang Y; Yuan F; Zhang Q; Shi X; Zhang L; Qin C; Zheng A
Emerg Microbes Infect; 2020 Dec; 9(1):2269-2277. PubMed ID: 32990161
[TBL] [Abstract][Full Text] [Related]
8. COVID-19 Coronavirus spike protein analysis for synthetic vaccines, a peptidomimetic antagonist, and therapeutic drugs, and analysis of a proposed achilles' heel conserved region to minimize probability of escape mutations and drug resistance.
Robson B
Comput Biol Med; 2020 Jun; 121():103749. PubMed ID: 32568687
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy.
Datta PK; Liu F; Fischer T; Rappaport J; Qin X
Theranostics; 2020; 10(16):7448-7464. PubMed ID: 32642005
[TBL] [Abstract][Full Text] [Related]
10. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses.
Schmidt F; Weisblum Y; Muecksch F; Hoffmann HH; Michailidis E; Lorenzi JCC; Mendoza P; Rutkowska M; Bednarski E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Caskey M; Robbiani DF; Nussenzweig MC; Rice CM; Hatziioannou T; Bieniasz PD
J Exp Med; 2020 Nov; 217(11):. PubMed ID: 32692348
[TBL] [Abstract][Full Text] [Related]
11. Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike.
Huo J; Zhao Y; Ren J; Zhou D; Duyvesteyn HME; Ginn HM; Carrique L; Malinauskas T; Ruza RR; Shah PNM; Tan TK; Rijal P; Coombes N; Bewley KR; Tree JA; Radecke J; Paterson NG; Supasa P; Mongkolsapaya J; Screaton GR; Carroll M; Townsend A; Fry EE; Owens RJ; Stuart DI
Cell Host Microbe; 2020 Sep; 28(3):445-454.e6. PubMed ID: 32585135
[TBL] [Abstract][Full Text] [Related]
12. Robust neutralization assay based on SARS-CoV-2 S-protein-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressing BHK21 cells.
Xiong HL; Wu YT; Cao JL; Yang R; Liu YX; Ma J; Qiao XY; Yao XY; Zhang BH; Zhang YL; Hou WH; Shi Y; Xu JJ; Zhang L; Wang SJ; Fu BR; Yang T; Ge SX; Zhang J; Yuan Q; Huang BY; Li ZY; Zhang TY; Xia NS
Emerg Microbes Infect; 2020 Dec; 9(1):2105-2113. PubMed ID: 32893735
[TBL] [Abstract][Full Text] [Related]
13. Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites.
Qiao B; Olvera de la Cruz M
ACS Nano; 2020 Aug; 14(8):10616-10623. PubMed ID: 32806067
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Hoffmann M; Kleine-Weber H; Schroeder S; Krüger N; Herrler T; Erichsen S; Schiergens TS; Herrler G; Wu NH; Nitsche A; Müller MA; Drosten C; Pöhlmann S
Cell; 2020 Apr; 181(2):271-280.e8. PubMed ID: 32142651
[TBL] [Abstract][Full Text] [Related]
15. Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development.
Samrat SK; Tharappel AM; Li Z; Li H
Virus Res; 2020 Oct; 288():198141. PubMed ID: 32846196
[TBL] [Abstract][Full Text] [Related]
16. Genetic predisposition models to COVID-19 infection.
Darbeheshti F; Rezaei N
Med Hypotheses; 2020 Sep; 142():109818. PubMed ID: 32416414
[No Abstract] [Full Text] [Related]
17. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
Pinto D; Park YJ; Beltramello M; Walls AC; Tortorici MA; Bianchi S; Jaconi S; Culap K; Zatta F; De Marco A; Peter A; Guarino B; Spreafico R; Cameroni E; Case JB; Chen RE; Havenar-Daughton C; Snell G; Telenti A; Virgin HW; Lanzavecchia A; Diamond MS; Fink K; Veesler D; Corti D
Nature; 2020 Jul; 583(7815):290-295. PubMed ID: 32422645
[TBL] [Abstract][Full Text] [Related]
18. Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice.
Liu X; Drelich A; Li W; Chen C; Sun Z; Shi M; Adams C; Mellors JW; Tseng CT; Dimitrov DS
Vaccine; 2020 Oct; 38(46):7205-7212. PubMed ID: 33010978
[TBL] [Abstract][Full Text] [Related]
19. A vesicular stomatitis virus-based prime-boost vaccination strategy induces potent and protective neutralizing antibodies against SARS-CoV-2.
Kim GN; Choi JA; Wu K; Saeedian N; Yang E; Park H; Woo SJ; Lim G; Kim SG; Eo SK; Jeong HW; Kim T; Chang JH; Seo SH; Kim NH; Choi E; Choo S; Lee S; Winterborn A; Li Y; Parham K; Donovan JM; Fenton B; Dikeakos JD; Dekaban GA; Haeryfar SMM; Troyer RM; Arts EJ; Barr SD; Song M; Kang CY
PLoS Pathog; 2021 Dec; 17(12):e1010092. PubMed ID: 34914812
[TBL] [Abstract][Full Text] [Related]
20. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction.
Tan CW; Chia WN; Qin X; Liu P; Chen MI; Tiu C; Hu Z; Chen VC; Young BE; Sia WR; Tan YJ; Foo R; Yi Y; Lye DC; Anderson DE; Wang LF
Nat Biotechnol; 2020 Sep; 38(9):1073-1078. PubMed ID: 32704169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
